Posts in Category: ADC Technology

Upwork Makes Earning Online Easier

Clients on Upwork can interview and hire freelancers in various sectors from across the globe on its online platform. With over 15 Million users across 180 countries and with a freelancer billing of $1 billion annually, Upwork is the largest freelancer market. Based in California, the company is set to file an IPO (Initial Public Offering.) The company rebranded in 2015 after the merger of Elance, founded 1999, and oDesk, founded 2003. A virtual profile serves as a résumé, and without one it is impossible to get work. Honesty is paramount when filling out what you are skilled in and level of expertise. Failure to deliver on a project you accepted could lead to blacklisting or account closure.

Upwork is a crowd-sourcing platform that has eased the logistics between client and professional. With 3 million jobs posted annually, the site also runs a blog that lets people write on various subjects. These articles touch on everyday issues and are written by people with experience and recently to-do lists were on the agenda. It might sound a little petty, but this list does more than manage your time.

No matter how busy one is, an incomplete task with weigh down your mind casing stress and you even lose focus of the task you are already handling. This is scientifically true and is known as the Zeigernik Effect; therefore a to-do list will help enhance your concentration while saving you time, more haste, less speed. By writing down all our tasks on a to-do list, you give your mind freedom from holding on to it thus your attention can be used fully for the current task.

When setting priorities, we always assume that the most urgent should be at the top; this is not always the truth. When setting priorities, do not look at just the deadlines, the timing of a task can make a world of difference, know which task is suited to what time of day. Lastly, do not create your to-do list in the morning, which should be used to tackle the most important task, to-do lists should be made the evening before.

Who Is NewsWatch TV, And Why Have They Earned Such Positive Reviews?

Devoted to delivering factual, impartial, and enthralling accounts of the news, NewsWatch TV is a media outlet you can trust. The topics they report on run the gamut from technology trends to entertainment news. Both seasoned and prestigious, NewsWatch TV has won many steadfast advocates and loyal viewers over the years. When NewsWatch TV launched in 1990, this production company likely had no idea they’d be celebrating their 1,000th episode 25 years later. In the time that NewsWatch TV has reported news, stories of public policy, medical breakthroughs, financial calamities, travel opportunities, philanthropic matters, and legal issues have been recounted. These highlights are only a drop in the bucket.

NewsWatch TV earned such a prominent role in their domain that A-list celebrities began appearing on their program. No doubt a tremendous feat, NewsWatch TV was well on their way to becoming a top dog in the media industry. Far more than a star-studded interview network, NewsWatch TV is a dependable news source for upwards of 100 million people. An extensive audience no doubt, NewsWatch TV works diligently to ensure that nothing less than fact-based and reliable information is conveyed.

NewsWatch TV’s commitment to recounting truthful news is in large part why they’ve earned an outpouring of praise from both their partners and viewers. In fact, brands often team up with NewsWatch TV in the hopes of conveying their products to a broad audience, in turn driving sales and converting leads. Avanca, Contour Design, Saygas, and Steelseries are a few companies who’ve partnered alongside NewsWatch TV, and they couldn’t be happier with the results NewsWatch TV delivered. In fact, all four brands commend NewsWatch TV for their keen understanding of the market, profound wisdom, and powerful execution. Above all else, many applaud NewsWatch TV for the tremendous effort they put into their craft.

Find out more about NewsWatch TV Reviews: https://newswatchtvreviews.wordpress.com/

 

Clay Siegall giving hope to patients with under-researched cancer types

Despite the remarkable gains made in the survivability of many types of cancer throughout the 20th century, throughout the latter half of the 20th century and into the 2000s, many types of cancer have seen a deep stagnation in the improvement of their survival rates. Nowhere has this been truer than in the case of cancer types such as pancreatic cancer, hepatocellular carcinoma and non-Hodgkin’s lymphoma.

One man, Clay Siegall, is doing all he can to bring new forms of revolutionary treatment to some of these under-researched and undertreated cancer types. After founding Seattle Genetics, the only pharmaceutical giant solely dedicated to the creation of a new class of drugs known as antibody drug conjugates, Dr. Siegall made it known that his chief strategy would be to go after undertreated and under-researched cancer types, potentially adding large incremental gains to the survivability of cancers that have not seen major improvements over the last 20 to 30 years.

Throughout the 2000s, Seattle Genetics began developing a class of drugs that would fight against refractory non-Hodgkin’s lymphoma. Due to a number of factors, non-Hodgkin’s lymphoma had been largely ignored by the medical research community over the preceding 30 years. The disease is often not nearly as deadly as some other types of cancer. However, it is still a very real malignancy and eventually takes the life of up to half of the people who have it. For this reason and many others, it was not considered a top priority.

But Dr. Siegall began creating the first treatment to markedly improve the survivability of non-Hodgkin’s lymphoma in years. Known as ADCetris, this remarkable antibody drug conjugate has been FDA-approved for the broad scale use in refractory non-Hodgkin’s lymphoma, leading to thousands of lives having been saved and proving the concept of antibody drug conjugates in general.

ADCetris also has a number of off-label uses that are currently in phase-three FDA trials, which may lead to the eventual approval of this drug for dozens of other off-label uses. Through efforts like these, Seattle Genetics is making real progress in reducing the mortality rates of many different types of cancer, saving lives and potentially leading to an eventual cure.